Greg Zante, Chief Financial Officer at Viking Therapeutics, Inc. (VKTX), sold 95,918 shares at $43.32 ($4.1M) on 2025-01-06, disclosed to the SEC on 2025-01-06.
Seasonal sale ($4.1M) by Chief Financial Officer — this insider has traded VKTX in January in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.69 | 45,609 | $1.9M | 47.5% |
| 2 | $42.69 | 45,609 | $1.9M | 47.5% |
| 3 | $43.32 | 4,700 | $204K | 5.0% |
| Total | $42.72 avg | 95,918 | $4.1M | 100% |
| Filing → |
| VKTX | SELL | 2025-10-28 | $216K | — | Filing → |
| VKTX | SELL | 2025-07-03 | $237K | — | Filing → |
| VKTX | SELL | 2024-10-28 | $19.7M | — | Filing → |